Public Page
INOLYSIS
INOLYSIS is a biotech start-up developing first-in-class small-molecule therapeutics for fibrosis, targeting key yet underexplored disease regulators. Backed by a strong patent portfolio, our lead candidate shows robust preclinical efficacy. We aim to deliver safer, more effective treatments for patients
Healthtech / HealthcarePre-seedGreece
Interested in INOLYSIS?
Request access to the full data room to review financials, documents and due diligence materials.